Related Experiment Videos
A comparison of low dose levamisole and penicillamine in rheumatoid arthritis
Abstract:
Levamisole (150 mg once weekly) was compared with penicillamine (250 mg daily) in a single blind independent observer study in 28 patients with rheumatoid arthritis over twelve months. Fifty percent (8/16) of patients stopped levamisole, five within three months of starting, while only two of twelve stopped penicillamine. In those patients able to tolerate treatment for twelve months, both regimens produced a significant and comparable reduction in disease activity, with the onset of action of penicillamine occurring at three months compared with six to nine months for levamisole. Radiological progression of disease occurred in both groups. Levamisole in low dose may improve parameters of disease activity in rheumatoid arthritis but poor patient tolerance, slow onset of action and failure to prevent radiological progression limit its usefulness.
Insights
Levamisole showed some benefit for rheumatoid arthritis but was poorly tolerated. Penicillamine was better tolerated and had a faster onset of action, though neither prevented radiological progression.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and potential joint destruction.
- Disease-modifying antirheumatic drugs (DMARDs) are crucial for managing RA, with ongoing research into optimal treatment strategies.
- Levamisole and penicillamine are established DMARDs with distinct mechanisms and side effect profiles.
Purpose of the Study:
- To compare the efficacy and tolerability of levamisole versus penicillamine in patients with rheumatoid arthritis over a twelve-month period.
- To assess the onset of action and impact on radiological progression for both treatment regimens.
- To evaluate the overall clinical usefulness of low-dose levamisole in RA management.
Main Methods:
- A single-blind, independent observer study involving 28 patients diagnosed with rheumatoid arthritis.
- Patients were randomized to receive either levamisole (150 mg weekly) or penicillamine (250 mg daily) for twelve months.
- Data collection included assessment of disease activity, patient tolerance, onset of action, and radiological progression.
Main Results:
- Fifty percent of patients discontinued levamisole, with five stopping within three months due to intolerance.
- Only two out of twelve patients stopped penicillamine, indicating better tolerability.
- Both treatments demonstrated comparable reductions in disease activity among patients who completed twelve months, with penicillamine showing a faster onset (3 months vs. 6-9 months for levamisole).
- Radiological progression was observed in both treatment groups.
Conclusions:
- Low-dose levamisole may offer some improvement in rheumatoid arthritis disease activity parameters.
- However, poor patient tolerance and a slow onset of action significantly limit levamisole's clinical utility in RA.
- Levamisole failed to prevent radiological progression, similar to penicillamine, highlighting the need for more effective RA therapies.